HOME > TOP STORIES
TOP STORIES
-
BUSINESS 70% of Major Products Fall Victim to Off-Year Drug Re-Pricing: Jiho Tally
March 10, 2021
-
BUSINESS Top-Tier Drug Makers Face 2-4% Cuts, Mid-Sized Firms 6-8% in Japan’s First Off-Year Re-Pricing: Tally
March 9, 2021
-
BUSINESS Top-3 Generic Makers Hit with Average 9.8% Price Cut in Off-Year Revision: Jiho Tally
March 9, 2021
-
BUSINESS Takeda Aims for Mid-Teens Annual Growth in Japan Oncology Biz: Exec
March 8, 2021
-
REGULATORY MHLW Presents Views on “Pharma Industry Vision 2021” to LDP’s Project Team
March 8, 2021
-
REGULATORY Japan Confirms 1st Case of Anaphylaxis from COVID-19 Vaccination
March 8, 2021
-
REGULATORY Japan to Review Moderna Vaccine with Top Priority, May OK Possible: Minister
March 8, 2021
-
BUSINESS Takeda Submits NDA for Moderna Vaccine in Japan
March 5, 2021
-
REGULATORY Pfizer, Bayer to Pull Plug on “G1” Products with High Generic Erosions
March 5, 2021
-
REGULATORY MHLW Announces New Drug Prices for 1st Off-Year Revision in April
March 5, 2021
-
ORGANIZATION Fast-Track Approval System, New Pricing Rules Needed for Therapeutic Apps: DTx Consortium
March 5, 2021
-
BUSINESS Nichi-Iko Chief Apologizes for GMP Violations, but Draws Clear Distinction from Kobayashi Kako Case
March 4, 2021
-
BUSINESS AbbVie Japan to Boost Immunology Reps as It Gears Up for Rinvoq/Skyrizi Label Expansions
March 3, 2021
-
REGULATORY Nichi-Iko Ordered to Suspend Biz over Sloppy Manufacturing
March 3, 2021
-
REGULATORY Woman Dies 3 Days after COVID-19 Vaccine Shot, but Link Indeterminable
March 3, 2021
-
BUSINESS Iwasaki to Bow Out as Chief of Takeda’s Japan Pharma Biz Unit
March 3, 2021
-
BUSINESS Kyowa Kirin Poised to Speed Up Growth with 5 Strategic Launches, Eyes Blockbuster Potential in Eczema Med
March 2, 2021
-
REGULATORY Nichi-Iko to Get Business Suspension Order on March 3
March 2, 2021
-
BUSINESS Takeda to Offload 4 Diabetes Meds in Japan to Teijin for 133 Billion Yen
March 1, 2021
-
REGULATORY Govt to Deliver 1st COVID-19 Vaccine Dose for 3.7 Million HCPs in April: Minister
March 1, 2021
ページ
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
